Project Details
Projekt Print View

Vitamin C-induzierte DNA-Demethylierung als Präventivtherapie für Leukämie

Subject Area Hematology, Oncology
Term from 2020 to 2023
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 446251518
 
Mutations in genes that either encode or affect the function of epigenetic regulators are frequent early events in aging-related clonal hematopoiesis and were found to precede leukemic transformation in longitudinal patient studies. Correspondingly, a large proportion of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients show genome-wide alterations in chromatin methylation. Recent work, including the host lab’s, has identified gains in cytosine methylation at enhancer elements in response to isocitrate dehydrogenase (IDH) and ten-eleven translocation dioxygenase (TET) mutations to directly affect myeloid differentiation in murine models. The host lab showed that vitamin C, which activates a set of enzymes that catalyze genome demethylation, can resolve enhancer hypermethylation and thereby re-initiate expression of key myeloid genes in vitro. These findings suggest that TET and IDH mutations actively contribute to the block of differentiation that is a hallmark of AML and that this can be readily reversed by a known, non-toxic molecule. In this proposal, I suggest to explore the efficacy of vitamin C both individually and in combination with other demethylating therapies in pre-clinical in vivo settings. Further, considering that TET and IDH mutations can be detected in individuals prior to disease outbreak using routine diagnostic techniques, I propose to explore the potential of high dose vitamin C supplementation to restore cytosine methylation homeostasis in affected cells with the ultimate goal to delay or prevent the transformation towards myeloid malignancy.
DFG Programme WBP Fellowship
International Connection Canada
 
 

Additional Information

Textvergrößerung und Kontrastanpassung